NanoViricides Inc. (NNVC)

[leifsmith]

If someone could figure out who are the health workers most likely be sent to Ebola outbreak regions and educate them about the promise of EbolaCide a significant number of these people, after doing their own analysis of comparative risks, might decide to try EbolaCide. The statistical results of that trial would provide a lot of information. They would most likely want to wait to see some success in animal trials before the benefit/risk ratio would be convincing.

No need to respond to this by saying it doesn't follow the established rules for initiation of drug use. It doesn't. But those rules become fragile as Ebola marches on.